Triptorelin is a GnRH agonist that results in reversible biochemical castration, and its role in treating patients with prostate cancer is well established [13, 14]; however, its efficacy on the primary symptoms of prostate cancer, such as LUTS, has not yet been extensively studied [9, 11, 15, 16]. The gene discussed is GNRH1; the disease is prostate cancer.